Semnur Pharmaceuticals, Inc. (SMNRW) — SEC Filings
Semnur Pharmaceuticals, Inc. (SMNRW) — 50 SEC filings. Latest: S-1/A (Dec 19, 2025). Includes 27 8-K, 7 SC 13G/A, 6 10-Q. AI-decoded analysis.
View Semnur Pharmaceuticals, Inc. on SEC EDGAR
Overview
Semnur Pharmaceuticals, Inc. (SMNRW) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a S-1/A filed on Dec 19, 2025: Semnur Pharmaceuticals, Inc. (SMNRW) filed an S-1/A on December 19, 2025, primarily for the registration of up to 203,737,349 shares of Common Stock and up to 8,760,000 shares issuable upon warrant exercise, along with 510,000 Private Warrants. The company will not receive proceeds from the resale o
Sentiment Summary
Across 50 filings, the sentiment breakdown is: 6 bearish, 44 neutral. The dominant filing sentiment for Semnur Pharmaceuticals, Inc. is neutral.
Filing Type Overview
Semnur Pharmaceuticals, Inc. (SMNRW) has filed 1 S-1/A, 27 8-K, 6 10-Q, 1 S-1, 2 10-K, 2 DEF 14A, 7 SC 13G/A, 1 SC 13D, 3 SC 13G with the SEC between Feb 2024 to Dec 2025.
Filings by Year
Recent SEC Filings (50)
Risk Profile
Risk Assessment: Of SMNRW's 40 recent filings, 6 were flagged as high-risk, 13 as medium-risk, and 21 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | N/A |
| Net Income | -$152.6M |
| EPS | N/A |
| Debt-to-Equity | N/A |
| Cash Position | $85K |
| Operating Margin | N/A |
| Total Assets | $774K |
| Total Debt | $15.4M |
Key Executives
- Jaisim Shah
Industry Context
Semnur Pharmaceuticals operates within the highly competitive and regulated biotechnology and pharmaceutical sector. The industry is characterized by long development cycles, high R&D costs, and significant regulatory hurdles. Success often depends on innovation, intellectual property protection, and the ability to navigate complex clinical trial and approval processes.
Top Tags
filing (10) · spac (9) · 8-K (8) · material-agreement (5) · 10-Q (5) · warrants (5) · corporate-structure (5) · quarterly-report (4) · SPAC (4) · Biotechnology (3)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Common Stock Price | $20.00 | Last reported sales price per share on December 17, 2025 |
| Public Warrant Price | $0.15 | Last reported sales price per warrant on December 17, 2025 |
| Shares for Resale | 203,737,349 | Maximum aggregate shares of Common Stock offered by Selling Stockholders |
| Shares Issuable from Warrants | 8,760,000 | Maximum aggregate shares of Common Stock issuable upon exercise of Warrants |
| Private Warrants | 510,000 | Number of Private Warrants offered by Selling Warrantholders |
| Scilex Shares | 188,554,849 | Shares of Common Stock held by Scilex Holding Company for resale |
| Biconomy Resale Shares | 12,500,000 | Shares of Common Stock held by Biconomy PTE.LTD for resale |
| Business Combination Date | September 22, 2025 | Date of consummation of the merger with Legacy Semnur |
| Public Warrants | 8,250,000 | Number of Public Warrants originally sold to public investors |
| Common Stock Par Value | $0.0001 | Par value per share of Semnur's Common Stock |
| Net Loss | $152.6M | for the three months ended September 30, 2025, a significant increase from $1.3M in the prior year |
| General and Administrative Expenses | $151.5M | for the three months ended September 30, 2025, largely due to stock-based compensation |
| Stock-based Compensation | $140.4M | for the nine months ended September 30, 2025, primarily from the business combination |
| Cash and Cash Equivalents | $85K | as of September 30, 2025, indicating critically low liquidity |
| Total Current Liabilities | $10.0M | as of September 30, 2025, significantly higher than cash reserves |
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Semnur Pharmaceuticals, Inc. (SMNRW)?
Semnur Pharmaceuticals, Inc. has 50 recent SEC filings from Feb 2024 to Dec 2025, including 27 8-K, 7 SC 13G/A, 6 10-Q. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of SMNRW filings?
Across 50 filings, the sentiment breakdown is: 6 bearish, 44 neutral. The dominant sentiment is neutral.
Where can I find Semnur Pharmaceuticals, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Semnur Pharmaceuticals, Inc. (SMNRW) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Semnur Pharmaceuticals, Inc.?
Key financial highlights from Semnur Pharmaceuticals, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for SMNRW?
The investment thesis for SMNRW includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Semnur Pharmaceuticals, Inc.?
Key executives identified across Semnur Pharmaceuticals, Inc.'s filings include Jaisim Shah.
What are the main risk factors for Semnur Pharmaceuticals, Inc. stock?
Of SMNRW's 40 assessed filings, 6 were flagged high-risk, 13 medium-risk, and 21 low-risk.
What are recent predictions and forward guidance from Semnur Pharmaceuticals, Inc.?
Forward guidance and predictions for Semnur Pharmaceuticals, Inc. are extracted from SEC filings as they are enriched.